Abstract Background Subcutaneous treprostinil is a prostacyclin analogue used to treat pulmonary arterial hypertension (PAH). Due to local pain it can cause a deterioration of heart related quality of life (HRQoL) or even abandonment of treatment. The aim of this paper was to assess the feasibility of treatment with intravenous treprostinil administered by means of the Lenus Pro® implantable pump. Methods This was a retrospective, multi-center study involving 12 patients (8 females) with PAH treated with a subcutaneous infusion of treprostinil with intolerable pain at the infusion site. Clinical evaluation, including HRQoL assessment with SF-36 questionnaire was performed, before pump implantation and 2–9 months after. The median time of fo...
Continuous i.v. epoprostenol (prostacyclin) therapy improves survival and quality of life in patient...
Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease process with a high morbidi...
AbstractProstanoids have played a prominent role in the treatment of pulmonary arterial hypertension...
Objectives Parenteral prostanoids infused via external pumps are well-established pulmonary arterial...
BACKGROUND: We examined safety and long-term outcomes of intravenous treprostinil administered via t...
BACKGROUND: Prostacyclins improve symptoms and survival in pulmonary arterial hypertension (PAH). In...
Intravenous treprostinil administration by an implantable pump is an attractive option for pulmonary...
BACKGROUND: The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often...
BackgroundThe use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often l...
Nika Skoro-Sajer1, Irene Lang1, Robert Naeije21Division of Cardiology, Department of Internal Medici...
Pulmonary arterial hypertension (PAH) is fatal if untreated. Intravenous epoprostenol improves exer...
Background: Subcutaneous treprostinil has dose-dependent beneficial effects in patients with severe ...
Steven C Pugliese,1 Todd M Bull1,2 1Division of Pulmonary Sciences and Critical Care Medicine, Depar...
Implantable infusion pumps might improve the convenience and safety of intravenous treprostinil for ...
BackgroundParenteral prostanoids are effective treatment for pulmonary arterial hypertension, but lo...
Continuous i.v. epoprostenol (prostacyclin) therapy improves survival and quality of life in patient...
Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease process with a high morbidi...
AbstractProstanoids have played a prominent role in the treatment of pulmonary arterial hypertension...
Objectives Parenteral prostanoids infused via external pumps are well-established pulmonary arterial...
BACKGROUND: We examined safety and long-term outcomes of intravenous treprostinil administered via t...
BACKGROUND: Prostacyclins improve symptoms and survival in pulmonary arterial hypertension (PAH). In...
Intravenous treprostinil administration by an implantable pump is an attractive option for pulmonary...
BACKGROUND: The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often...
BackgroundThe use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often l...
Nika Skoro-Sajer1, Irene Lang1, Robert Naeije21Division of Cardiology, Department of Internal Medici...
Pulmonary arterial hypertension (PAH) is fatal if untreated. Intravenous epoprostenol improves exer...
Background: Subcutaneous treprostinil has dose-dependent beneficial effects in patients with severe ...
Steven C Pugliese,1 Todd M Bull1,2 1Division of Pulmonary Sciences and Critical Care Medicine, Depar...
Implantable infusion pumps might improve the convenience and safety of intravenous treprostinil for ...
BackgroundParenteral prostanoids are effective treatment for pulmonary arterial hypertension, but lo...
Continuous i.v. epoprostenol (prostacyclin) therapy improves survival and quality of life in patient...
Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease process with a high morbidi...
AbstractProstanoids have played a prominent role in the treatment of pulmonary arterial hypertension...